-
Indrayani Biotech to Invest in New Biosimilar Plant
Indrayani Biotech Ltd., a leading Indian biotechnology company, has announced plans to invest in a new biosimilar manufacturing plant. The new plant will be located in the Genome Valley region of Hyderabad, India.
-
Indrayani Biotech Receives USFDA Approval for Biosimilar Insulin
Indrayani Biotech Ltd. has received approval from the US Food and Drug Administration (USFDA) for its biosimilar insulin. The approval makes Indrayani Biotech the first Indian company to receive USFDA approval for a biosimilar insulin.
-
Indrayani Biotech Partners with Merck to Develop New Cancer Drugs
Indrayani Biotech Ltd. has entered into a partnership with Merck, a leading global pharmaceutical company, to develop new cancer drugs. The partnership will leverage Indrayani Biotech's expertise in biosimilar development and Merck's expertise in oncology.
-
Indrayani Biotech Collaborates with Prescience Point to Advance AI-Powered Crop Protection Solutions
Indrayani Biotech, a leading provider of microbial-based crop protection solutions, has announced a strategic collaboration with Prescience Point, a renowned provider of artificial intelligence (AI) and data analytics solutions for the agriculture industry. This partnership aims to leverage the power of AI to enhance Indrayani Biotech's crop protection offerings and drive innovation in sustainable agriculture.
-
Indrayani Biotech Announces Successful Field Trials of Novel Biofungicide Against Devastating Banana Disease
Indrayani Biotech, a pioneer in the development and manufacturing of microbial-based crop protection solutions, has achieved a significant milestone with the successful field trials of its novel biofungicide, IB-101, against Fusarium wilt, a devastating disease that affects banana plants worldwide.
-
Indrayani Biotech Secures Strategic Investment to Accelerate Global Expansion and Innovation
Indrayani Biotech, a leading provider of microbial-based crop protection solutions, has successfully secured a strategic investment from undisclosed investors. This investment will fuel the company's global expansion plans and accelerate its research and development efforts, enabling Indrayani Biotech to bring innovative and sustainable crop protection solutions to farmers worldwide.
-
Indrayani Biotech Launches New Biofertilizer for Sustainable Agriculture
Indrayani Biotech Ltd., a leading biotechnology company, has announced the launch of its new biofertilizer, NitroGrow, designed to promote sustainable agriculture practices.
-
Indrayani Biotech and ICAR Collaborate on Agricultural Research
Indrayani Biotech Ltd. and the Indian Council of Agricultural Research (ICAR) have entered into a collaboration to conduct joint research projects focused on developing innovative agricultural technologies.
-
Indrayani Biotech Wins Award for Excellence in Biotechnology
Indrayani Biotech Ltd. has been recognized for its outstanding contributions to the field of biotechnology by receiving the prestigious 'Excellence in Biotechnology Award' from the Confederation of Indian Industry.
-
Indrayani Biotech Ltd. Announces Positive Results from Phase 2 Clinical Trial of IND-003 in Advanced Prostate Cancer
Indrayani Biotech Ltd. (IBL), a clinical-stage biopharmaceutical company, today announced positive results from a Phase 2 clinical trial of IND-003, its lead product candidate for the treatment of advanced prostate cancer. The trial met its primary endpoint of demonstrating a statistically significant improvement in overall survival (OS) in patients treated with IND-003 compared to patients treated with standard of care.
-
Indrayani Biotech Ltd. to Present Data from Phase 2 Clinical Trial of IND-003 at the American Society of Clinical Oncology (ASCO) Annual Meeting
Indrayani Biotech Ltd. (IBL), a clinical-stage biopharmaceutical company, today announced that it will present data from a Phase 2 clinical trial of IND-003, its lead product candidate for the treatment of advanced prostate cancer, at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 2-6, 2023, in Chicago, Illinois.
-
Indrayani Biotech Ltd. Announces Initiation of Phase 3 Clinical Trial of IND-003 in Advanced Prostate Cancer
Indrayani Biotech Ltd. (IBL), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 3 clinical trial of IND-003, its lead product candidate for the treatment of advanced prostate cancer. The trial will enroll approximately 600 patients with advanced prostate cancer who have failed standard of care therapy.
-
Indrayani Biotech receives DCGI approval for phase 2 clinical trial of IB-1001 for treatment of solid malignancies
Indrayani Biotech Limited (IBL), a clinical stage biopharmaceutical company, today announced that it has received approval from the Drugs Controller General of India (DCGI) to conduct a Phase 2 clinical trial of its lead molecule, IB-1001, for the treatment of solid malignancies.
-
Indrayani Biotech announces positive preclinical data for IB-1001 in combination with PD-1 inhibitor
Indrayani Biotech Limited (IBL), a clinical stage biopharmaceutical company, today announced positive preclinical data for its lead molecule, IB-1001, in combination with a PD-1 inhibitor.
-
Indrayani Biotech receives IND clearance from US FDA for phase 1 clinical trial of IB-1001
Indrayani Biotech Limited (IBL), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for IB-1001, the company's lead molecule, to initiate a Phase 1 clinical trial in the United States.
-
Indrayani Biotech receives US FDA clearance for Anti-CD20 Antibody Drug Conjugate (ADC) IND
Indrayani Biotech Limited, a leading Indian biopharmaceutical company focused on developing and manufacturing novel biologics, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an Investigational New Drug (IND) application for its Anti-CD20 Antibody Drug Conjugate (ADC).
-
Indrayani Biotech receives US FDA Orphan Drug Designation for Anti-DLL4 Antibody for the treatment of SCLC
Indrayani Biotech Limited, a leading Indian biopharmaceutical company focused on developing and manufacturing novel biologics, today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its Anti-DLL4 Antibody for the treatment of Small Cell Lung Cancer (SCLC).
-
Indrayani Biotech and Biocon Biologics enter into a strategic partnership to develop and commercialize novel biosimilars
Indrayani Biotech Limited, a leading Indian biopharmaceutical company focused on developing and manufacturing novel biologics, today announced that it has entered into a strategic partnership with Biocon Biologics, a subsidiary of Biocon Limited, to develop and commercialize a portfolio of novel biosimilars.
-
Indrayani Biotech Announces GMP Certificate for Oncology Manufacturing Facility
Indrayani Biotech Ltd. has announced that its oncology manufacturing facility has been granted a Good Manufacturing Practices (GMP) certificate by the Central Drugs Standard Control Organization (CDSCO), India. This certification ensures that the facility meets the highest quality standards for the production of oncology products.
-
Indrayani Biotech Collaborates with Leading Oncology Hospital in India
Indrayani Biotech Ltd. has entered into a collaboration agreement with a leading oncology hospital in India to provide access to its innovative cancer treatments. This partnership will enable the hospital to offer a wider range of treatment options to its patients.
-
Indrayani Biotech Receives Funding for Oncology Research and Development
Indrayani Biotech Ltd. has secured a significant investment from a consortium of investors to support its ongoing research and development efforts in the field of oncology. This funding will enable the company to accelerate the development of new and innovative cancer treatments.